813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial.
Saved in:
| Title: | 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial. |
|---|---|
| Authors: | Frenel, J-S.1 (AUTHOR), Kim, J-W.2 (AUTHOR), Berton-Rigaud, D.1 (AUTHOR), Asher, R.3 (AUTHOR), Vidal, L.4 (AUTHOR), Pautier, P.5 (AUTHOR), Ledermann, J.A.6 (AUTHOR), Penson, R.T.7 (AUTHOR), Oza, A.M.8 (AUTHOR), Korach, J.9 (AUTHOR), Huzarski, T.10 (AUTHOR), Pignata, S.11 (AUTHOR), Colombo, N.12 (AUTHOR), Park-Simon, T-W.13 (AUTHOR), Tamura, K.14 (AUTHOR), Sonke, G.S.15 (AUTHOR), Freimund, A.16 (AUTHOR), Lee, C.K.17 (AUTHOR), Pujade-Lauraine, E.18 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS615-S615. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.952 |
